pipette
ENEnglish

Mavacamten and Obstructive Hypertrophic Cardiomyopathy in Teens

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Esta revista no permite republicar el resumen completo. Estas son las dos oraciones que eligió Pipette, citadas textualmente. El resto está en el sitio de la editorial.

Resultado principal
To the Editor: In the Study of Mavacamten in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM), conducted by Rossano et al. (July 23 issue), 1 two patients in the mavacamten group had serious adverse cardiac events, including one patient with episodes of syncope that were deemed by the investigator to be related to mavacamten.
Limitación que admiten los autores
It would have been helpful to determine the activity of the cytochrome P450 (CYP) enzyme CYP2C19 in that patient.

Apareció: viernes, 23 de octubre. New England Journal of Medicine. Revista con revisión por pares.

DOI: 10.1056/nejmc2611023